WASHINGTON–(BUSINESS WIRE)–New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation Reduction Act’s (IRA) drug pricing provisions. In fact, the study suggests some patients may pay more. In a research brief commissioned by We Work For Health with analysis performed by the IQVIA Institute for Human Data Science, researchers estimated what patients will actually pay for the 10 Part D medicines chosen by the Centers for Medicare and Medic
Home › RSS › New Study: Patients Unlikely to See Out-Of-Pocket Drug Savings from the Inflation Reduction Act